A Phase 3 interventional study of high-resolution peripheral quantitative computed tomography (HR-pQCT) and Dual energy X-ray absorptiometry (DXA) in Low Bone Mass, Low Bone Mineral Density and Osteoporosis, sponsored by Amgen. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2014-04-02.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 24th largest by enrollment, is one of 4 that started in 2009, is one of 17 in phase 3, and was the 6th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2009, is one of 14 in phase 3, and was the 6th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
To evaluate the combined effect of denosumab treatment and discontinuation on cortical thickness at the distal radius by High Resolution-Peripheral Quantitative Computed Tomography (HR-pQCT). Participants randomized to either denosumab or placebo in the 20050179 (NCT00293813) study who completed that study (ie, attended an end of study visit) can be included in this study. At least 12 months should have elapsed since the patient's 20050179 end of study visit.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
This study's enrollment of 79 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Browse Osteoporosis, Postmenopausal studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.
Procedure: high-resolution peripheral quantitative computed tomography (HR-pQCT) · Procedure: Dual energy X-ray absorptiometry (DXA) · Biological: Denosumab · Drug: Placebo
Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
Bone densitometry assessments of the forearm by DXA on day 1.
Denosumab 60 mg subcutaneously every 6 months in the previous study
Placebo to denosumab subcutaneously every 6 months in the previous study
Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT
Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT
Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT
Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT
Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT
Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT
Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT
Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT
Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA
Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA
Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Percent Change of Total Radius BMD From the Parent Study Baseline by DXA
Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Actual Value of Serum Type I C-telopeptide
Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).
Time frame: Day 1
Actual Value of Procollagen Type 1 N-terminal Peptide
Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).
Time frame: Day 1
The first subject enrolled on 14-JUL-2009. The last subject enrolled on 12-MAY-2010
| Milestone | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Started | 39 | 40 |
| Completed | 39 | 40 |
| Not completed | 0 | 0 |
Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT | -5.5 (-8.3 to -2.8) | -1.8 (-4.8 to 1.2) |
Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT | -1.2 (-2.6 to 0.2) | 0.3 (-1.2 to 1.7) |
Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT | -1.0 (-1.7 to -0.3) | -0.0 (-0.8 to 0.8) |
Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT | 5.1 (2.3 to 8.0) | 5.9 (2.8 to 9.0) |
Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT | -6.4 (-7.8 to -5.1) | -4.6 (-5.9 to -3.3) |
Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT | -1.6 (-2.8 to -0.4) | 1.0 (-0.2 to 2.2) |
Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT | -1.0 (-1.7 to -0.3) | -0.6 (-1.4 to 0.2) |
Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT | 2.9 (1.0 to 4.9) | 6.8 (4.9 to 8.8) |
Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA | -2.0 (-3.3 to -0.8) | 0.0 (-1.2 to 1.2) |
Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA | -3.5 (-4.9 to -2.2) | -1.9 (-3.3 to -0.6) |
Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.
| Percent change | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Percent Change of Total Radius BMD From the Parent Study Baseline by DXA | -3.0 (-4.0 to -2.0) | -0.9 (-1.9 to 0.1) |
Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).
| ng/mL | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Actual Value of Serum Type I C-telopeptide | 0.6 (0.5 to 0.6) | 0.7 (0.6 to 0.7) |
Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).
| µg/L | Previous Placebo Treatment Group | Previous Denosumab Treatment Group |
|---|---|---|
| Actual Value of Procollagen Type 1 N-terminal Peptide | 49.8 (45.6 to 54.3) | 58.9 (54.1 to 64.2) |
Collected over AEs (serious only) were collected after informed consent and through 30 days after the study procedures, maximum time on study was 44 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Previous Placebo Treatment Group | — | 0/39 (0%) | — |
| Previous Denosumab Treatment Group | — | 0/40 (0%) | — |
| Age, Continuous(Years) | Previous Placebo Treatment Group | Previous Denosumab Treatment Group | Total |
|---|---|---|---|
| Mean | 63.9 ± 5.8 | 63.4 ± 6.5 | 63.7 ± 6.1 |
| Sex: Female, Male(Participants) | Previous Placebo Treatment Group | Previous Denosumab Treatment Group | Total |
|---|---|---|---|
| Female | 39 | 40 | 79 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Previous Placebo Treatment Group | Previous Denosumab Treatment Group | Total |
|---|---|---|---|
| Number | 39 | 40 | 79 |
| Months since last dose in 20050179(Months) | Previous Placebo Treatment Group | Previous Denosumab Treatment Group | Total |
|---|---|---|---|
| Mean | 32.1 ± 2.5 | 32.2 ± 2.7 | 32.1 ± 2.6 |
No study locations are listed for this record.
The record gives a start of Jul 2009, a primary completion of Jun 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →